Development of Anti-asthma Drugs

Derek R. Buckle, BSc, PhD, ARCS, DIC, CChem, FRSC
Manager, Anti-allergy Project

Harry Smith, BSc, DSc
Manager, Anti-asthma Project

Beecham Pharmaceuticals—Research Division
Biosciences Research Centre
Epsom, Surrey
## Contents

Introduction  *D.R. Buckle and H. Smith*  1

### Part 1 Asthma—the nature of the disease

1 **Asthma—the nature of the disease**  *Maurice H. Lessof*  9
   - Definition—what is asthma?  9
   - Natural history  13
   - Epidemiology  18
   - Pathological mechanisms  20

### Part 2 Mediators

2 **Histamine**  *John C. Foreman*  29
   - Introduction  29
   - Histamine release  31
   - Actions of histamine  47
   - Concluding remarks  49

3 **Leukotrienes**  *Priscilla J. Piper*  55
   - Introduction  55
   - Structure, formation and metabolism  56
   - Biological activities of the leukotrienes  60
   - Conclusions  68

4 **Platelet-activating factor**  *J.M. Lynch, G.S. Worthen and P.M. Henson*  73
   - Introduction  73
   - Historical overview of platelet-activating factor  73
   - Structure and metabolism of PAF  75
   - PAF production in inflammation  78
   - PAF-induced platelet stimulation  78
   - Other inflammatory effects of PAF  79
   - Physiology  80
Contents

Effects on smooth muscle 80
Effects of vascular permeability 81
Pharmacological modulation 82
Conclusion 83

5 Eosinophils and neutrophils  A. Barry Kay 89

Introduction 89
General properties of eosinophils and neutrophils 89
Allergy and the eosinophil 96
Allergy and the neutrophil 99
Inflammatory cells and the progression of asthma 99
Corticosteroids, eosinophils and neutrophils 102
Summary 103

6 Acetylcholine  Laurie J. Smith 107

Introduction 107
Acetylcholine as a neurotransmitter 107
The cholinergic nervous system in asthma 110
Summary 116

Part 3 Pharmacological approaches

Section 1 Competitive antagonists 121

7 H₁ antihistamines  Noemi Eiser 121

Introduction 121
Effects of H₁-receptor antagonists when given to asthmatics by various routes 124
Conclusions 128

8 SRS-A antagonists  J.R. Bantick, M.C. Holroyde, T.B. Lee and P. Sheard 133

Development of FPL 55712 133
Biological effects of FPL 55712 138
Characterization of leukotriene receptors 144
Other antagonists of SRS-A 146
Clinical evaluation of SRS-A antagonists 153
Prospects 154

9 Anti-cholinergic drugs  Gary E. Pakes 159

The history of anti-cholinergic drugs in asthma 160
Mode and site of action 161
Atropine sulphate and methonitrate 162
Thiazinamium 167
Deptropine 167
Ipratropium bromide 168
Oxitropium bromide 175
Conclusions 177
Section 2  Functional antagonists 185

10 Drugs acting at adrenoceptors  Ian F. Skidmore 185

Introduction 185
The development of $\beta_2$-adrenoceptor stimulants 185
Receptor classification: the pharmacological basis for selectivity of action 190
The biochemical basis of pharmacological activity: receptor–ligand interaction and activation of adenylate cyclase 191
The biochemical basis of pharmacological activity: consequences of elevating cyclic AMP 194
Clinical activity of drugs acting at $\beta_2$-receptors 196
$\alpha$ Antagonists in the treatment of asthma 199

11 Theophylline  Michael Cushley and Stephen T. Holgate 205

Introduction 205
Serum levels and clinical effects 207
The mechanism of action of theophylline at cellular level 210
Future developments 217

12 Prostaglandins and related compounds  Jehan Bagli 225

Introduction 225
Chemistry 226
Biology 243
Structure-activity relationships 244
Conclusions 257

Section 3  Inhibitors of mediator release 261

13 Disodium cromoglycate and compounds with similar activities  Derek R. Buckle 261

Introduction 261
Mechanism of action of disodium cromoglycate 262
Pharmacokinetics and clinical effectiveness of DSCG 267
Biological test systems for drugs of the DSCG type 268
Compounds with activities similar to DSCG in biological test systems 271
Structural rationalization of DSCG-like compounds 286
Conclusions and possible future developments 287

14 Corticosteroids  Stuart M. Harding 297

Introduction 297
Systemic steroids 298
Inhalational steroids and topical activity 299
Mechanisms of action 302
The future 309
15 Non-steroidal inhibitors of arachidonic acid metabolism  T. Y. Shen
and A. N. Tischler  315

Introduction  315
Phospholipase A₂ inhibitors  317
Inhibition of the cyclo-oxygenase pathway  318
Oxygen radicals  329
Inhibitors of the lipoxygenase pathway  331
Future developments  341

Section 4  Specific hyposensitization  349

16 Specific hyposensitization  David M. Moran
and Alan W. Wheeler  349

Introduction  349
Immunological and mechanistic considerations  351
Clinical studies  356
Development in conventional hyposensitization treatments  366
Newer approaches to hyposensitization therapy  372
Summary  379

Index  391